Showing results (1-10 of 248) with videos related to
Sort By:
Pageof 25
Best Practice & Research. Clinical Haematology|July 13, 2010
Is MRD eradication a desirable goal in CLL?Carol Moreno, Matthias Ritgen, Andy RawstronLeukemia|April 28, 2018
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatmentsPaolo Ghia, Andy RawstronSeminars in Hematology|July 23, 2004
Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patientsAndy Rawstron, Peter Hillmen, Richard HoulstonBlood Reviews|January 29, 2011
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studiesSebastian Böttcher, Matthias Ritgen, Peter DregerMethods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Flow cytometric MRD detection in selected mature B-cell malignanciesSebastian Böttcher, Matthias Ritgen, Michael KnebaHematology/Oncology Clinics of North America|April 9, 2013
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?Sebastian Böttcher, Michael Hallek, Matthias Ritgen, et al.Acta Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.Hematology. American Society of Hematology. Education Program|December 4, 2020
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapyCarol MorenoBritish Journal of Haematology|October 4, 2007
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 studySylvia Feyler, Andy Rawstron, Graham Jackson, et al.Pageof 25